VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2023 financial results on Wednesday, Feb. 21, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start ...

Bausch + Lomb Corporation (NYSE:BLCO) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET George Gadkowski - Vice President of Investor Relations and Business Insights Sam Eldessouky - Executive Vice President and Chief Financial Officer Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Douglas Miehm - RBC Capital Markets I would now like to turn the conference over to George Gadkowski, Vice President of Investor Relations and Business Insights. Please go ahead. Before we begin, I would l ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...

Bausch + Lomb Corporation (NYSE:BLCO) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET | --- | |-------------------------------------| | | | George Gadkowski - IR | | Brent Saunders - Chairman and CEO | | Sam Eldessouky - EVP and CFO | | Conference Call Participants | | Joanne Wuensch - Citi | | Douglas Miehm - RBC Capital Markets | | Larry Biegelsen - Wells Fargo | | Matt Miksic - Barclays | | Robbie Marcus - JPMorgan | | Craig Bijou - Bank of America | | Patrick Wood - Morgan Stanley | | | Greet ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other juri ...

Moving now to the Surgical segment, first quarter revenue was $183 million, an increase of 9% on a constant currency basis. Implantables grew by 2% on a constant currency basis driven by strong performance in the highmargin premium IOL portfolio, which was up 32% in constant currency. We continue to see momentum in our investor franchise, which includes both the mono focal and toric IOLs. On a constant currency basis, the enVista franchise grew by 26% in the quarter. At a broader level, we continue to belie ...

All allocations and estimates in these Condensed Consolidated Financial Statements are based on assumptions that management believes are reasonable. On an ongoing basis, management reviews its allocations and estimates to ensure that these allocations and estimates appropriately reflect changes in the Company's business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company's bu ...

Also, clearly, I think as part of this in terms of the margin. I think you realized that we'll fill a Monofocal IOLs were somewhere in the $100 to $150 per lens, whereas the premium lenses are somewhere in the, let's call it, $750 to $1,000 per lens, and the cost of goods is not dramatically different. So that's probably is going to help that that margin opportunity for the long-term. But to the slide that I have in the deck, I give the exact page here, but there really is a focus there on what we're thinki ...

BAUSCH+LOMB This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2023 first quarter outlook and assumption thereof), the planned spin-off or separation of the Company from Bausch Health Companies Inc. ("BHC ...

Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Canada 98-1613662 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K Commission File Number: 001-41380 Registrant's telephone number, including area code (905) 695-7700 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, No Par ...